Literature DB >> 598418

Plasma and urinary digoxin in thyroid dysfunction.

G M Shenfield, J Thompson, D B Horn.   

Abstract

The response to a single oral dose of 0.5 mg digoxin has been studied in eight patients, of whom four were hyperthyroid and four were hypothyroid, both before and after treatment for their thyroid dysfunction. The post-dose plasma digoxin levels were significantly lower in the hyperthyroid patients when they were thyrotoxic than when they became euthyroid. In only one hypothyroid patient was the post-dose plasma digoxin level significantly higher before treatment than it was after and in the others the digoxin values reached were either the same as, or lower than, before treatment. There was a significant correlation between the creatinine clearance and the urinary concentrations of digoxin and these both altered with change in thyroid status. Total urinary digoxin excretion did not change. Pharmacokinetic analysis suggested that digoxin was distributed in a way compatible with a two-compartment model and that the volume of the central compartment was high in thyrotoxic patients and low in hypothyroid patients. In both cases it reverted to a median value after treatment. It is recommended that plasma digoxin levels should be monitored in all patients with thyroid dysfunction who require therapeutic digoxin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 598418     DOI: 10.1007/bf00561063

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Contrasting effects of thyroxin on zoxazolamine and hexobarbital metabolism.

Authors:  A H CONNEY; L GARREN
Journal:  Biochem Pharmacol       Date:  1961-06       Impact factor: 5.858

2.  The thyroid and the heart.

Authors:  H COOKSON
Journal:  Br Med J       Date:  1959-01-31

Review 3.  Digoxin therapy: textbooks, theory and practice.

Authors:  J K Aronson; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Death from thyrotoxicosis.

Authors:  J L Parker; D H Lawson
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

5.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

6.  Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat.

Authors:  F B Thomas; J H Caldwell; N J Greenberger
Journal:  Ann Intern Med       Date:  1973-05       Impact factor: 25.391

7.  Proceedings: Changes in drug metabolizing ability in thyroid disease.

Authors:  J Crooks; A J Hedley; C Macnee; I H Stevenson
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

8.  Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications.

Authors:  D J Sumner; A J Russell
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

Review 9.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Rat hepatic sodium plus potassium ion-dependent adenosine triphosphatase after treatment with digoxin and thyroxine.

Authors:  R Lindsay; J L Parker
Journal:  Clin Sci Mol Med       Date:  1976-05
View more
  13 in total

1.  Heart failure in thyrotoxicosis, an approach to management.

Authors:  R P Choudhury; J MacDermot
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 3.  Acute and emergency care for thyrotoxicosis and thyroid storm.

Authors:  Alzamani Mohammad Idrose
Journal:  Acute Med Surg       Date:  2015-05-12

Review 4.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

7.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Pharmacokinetics of digoxin in pregnancy.

Authors:  A M Luxford; G S Kellaway
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells.

Authors:  Naoki Nishio; Toshiya Katsura; Ken-ichi Inui
Journal:  Pharm Res       Date:  2007-11-15       Impact factor: 4.200

10.  Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells.

Authors:  D Kim; T W Smith
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.